[雷珠单抗治疗弹性假黄瘤继发脉络膜新生血管：2例报告]
[Choroidal neovascularization secondary to pseudoxanthoma elasticum treated with ranibizumab: a report of 2 cases].
作者信息
González-Gómez A, Morillo M J, González-Escobar A B, García-Campos J M
机构信息
Servicio de Oftalmología, Hospital Universitario Virgen de la Victoria, Málaga, España. anagg
出版信息
Arch Soc Esp Oftalmol. 2012 May;87(5):153-6. doi: 10.1016/j.oftal.2011.06.015. Epub 2012 Mar 19.
CASE REPORT
We report 2 cases of pseudoxanthoma elasticum with angioid streaks and choroidal neovascularization (CNV) in both eyes. Intravitreal ranibizumab (Lucentis) was administered with successful results in both cases.
DISCUSSION
CNV has been reported to occur in 72% to 86% of patients with angioid streaks. Although uncommon, the impact of CNV is important because it tends to affect people of working age. Based on the effectiveness of ranibizumab in other secondary CNVs, we decided to use it in our patients, observing the functional and anatomical improvement.
病例报告
我们报告2例双眼患有弹性假黄瘤伴血管样条纹和脉络膜新生血管（CNV）的病例。玻璃体内注射雷珠单抗（Lucentis），两例均取得成功。
讨论
据报道，72%至86%的血管样条纹患者会出现CNV。虽然不常见，但CNV的影响很重要，因为它往往影响工作年龄段的人群。基于雷珠单抗在其他继发性CNV中的有效性，我们决定在患者中使用它，并观察其功能和解剖学上的改善情况。
Zotero 插件